Search

Your search keyword '"Victoria Neches García"' showing total 2 results
Start Over Author "Victoria Neches García"
2 results on '"Victoria Neches García"'

1. Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments

Author

Laura-Amanda Vallejo Aparicio, Victoria Neches García, Beatriz Hernández-Novoa, Gregorio Casado, Ferrán Jodar, Marco Pinel, and Daniel Callejo Velasco

Subjects
Antiretroviral agents, Cabotegravir, Costs and cost analysis, Healthcare resource use, HIV, Long-acting injectable, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Introduction HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB + RPV LA vs. daily oral ART at National Health System (NHS) hospitals. Methods Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022). Results 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART. Conclusions These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.

Published
2024
Full Text
View/download PDF

2. Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain

Author

Victoria Neches García, Laura Amanda Vallejo-Aparicio, Afisi S Ismaila, Antoni Sicras-Mainar, Aram Sicras-Navarro, Cruz González, Rafael Cuervo, Soham Shukla, and Marcos García-Peñuela

Subjects
Male, General Medicine, Muscarinic Antagonists, Pneumonia, International Journal of Chronic Obstructive Pulmonary Disease, Bronchodilator Agents, Pulmonary Disease, Chronic Obstructive, Adrenal Cortex Hormones, Spain, Administration, Inhalation, Humans, Female, Adrenergic beta-2 Receptor Agonists, Aged, Retrospective Studies
Abstract

Victoria Neches García,1 Laura Amanda Vallejo-Aparicio,1 Afisi S Ismaila,2,3 Antoni Sicras-Mainar,4 Aram Sicras-Navarro,4 Cruz González,5 Rafael Cuervo,6 Soham Shukla,2 Marcos García-Peñuela6 1Market Access, GlaxoSmithKline, Madrid, Spain; 2Value Evidence and Outcomes, GlaxoSmithKline, Collegeville, PA, USA; 3Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; 4Real Life Data, Atrys Health, Barcelona, Spain; 5Pneumology Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain; 6Medical Affairs, GlaxoSmithKline, Madrid, SpainCorrespondence: Victoria Neches García, Market Access, GlaxoSmithKline, P.T.M Severo Ochoa, 2 28760 Tres Cantos, Madrid, Spain, Tel +34 677 50 37 57, Email victoria.x.neches@gsk.comPurpose: To determine the clinical and economic impact of inhaled corticosteroid (ICS) withdrawal in Spanish patients with COPD receiving triple therapy (TT) with ICS, long-acting β2-agonist (LABA), and long-acting muscarinic antagonist (LAMA).Patients and Methods: This was an observational, retrospective study of BIG-PAC database medical records. Patients aged ≥ 40 years receiving TT from 2016 to 2018 were followed for 1 year. Two cohorts were identified: patients continuing TT (ICS+LABA+LAMA), and patients receiving TT with ICS withdrawn (LABA+LAMA). Variables included medication, exacerbations (moderate and severe), pneumonia, mortality, health resource use (HRU), and cost per patient/year. Cohorts were compared using propensity score matching (PSM). Multivariate statistical analysis using analysis of covariance and Cox proportional risks was conducted.Results: Of 6541 patients included, 5740 (87.8%) continued TT and 801 (12.2%) had ICS withdrawn. Patients with ICS withdrawal were younger, had lower disease burden, higher ICS doses, and more exacerbations compared with those continuing ICS. PSM matched 795 patients in each cohort. Mean age was 68.5 years (SD: 11.2), 69.9% were male, and mean Charlson index was 2.0. Patients with ICS withdrawal had more total exacerbations in the 12 months following withdrawal compared with patients continuing TT (36.6% vs 31.4%; p=0.030). No significant differences were found for pneumonia (3.3% vs 3.6%; p=0.583) and mortality (9.9% vs 7.5%; p=0.092). Median time to first exacerbation was shorter in patients with ICS withdrawal compared with those continuing ICS (HR: 0.69, 95% CI: 0.57– 0.83; p< 0.001). Mean health cost per patient/year among patients with ICS withdrawal was higher than those continuing TT (€ 2993 vs € 2130; p< 0.001).Conclusion: ICS withdrawal in patients with COPD receiving TT was associated with increased exacerbations, HRU, and costs compared with continuing TT, with health and economic impacts on patients and the Spanish National Healthcare System, respectively. Pneumonia and mortality rates were similar between groups.Keywords: inhaled corticosteroid withdrawal, COPD, exacerbations, resource use, health costs

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results